*Sponsored by Lifewater Media. Please see disclosures below. |
| "CTXR" Releases Big News On Clinical Trial Results |
| | | | | | | | | Here's the key part to pay attention to: "The preliminary results from this Phase I trial of patients with recurrent gynecological cancers are highly encouraging. This novel chemo-free immunomodulatory combination regimen has been well tolerated, including at the highest dosage. This efficacy data strongly suggests that LYMPHIR may have the ability to improve and prolong the anti-tumor activity of immune checkpoint inhibitors. To date, this unique regimen has not been associated with significant immune-related adverse events. Moreover, of the 15 evaluable patients, one third experienced a clinical benefit with a median of more than 12 months of progression free survival," stated Dr. Myron Czuczman, Chief Medical Officer of Citius Pharmaceuticals and Citius Oncology. | On top of that- The recent FDA approval of LYMPHIR offers a unique catalyst opportunity for Citius Pharma, positioning it as the first targeted therapy for cutaneous T-cell lymphoma (CTCL) that directly affects the IL-2 receptor on malignant cells. This approval, combined with its inclusion in the NCCN Guidelines, boosts LYMPHIR's credibility and accessibility, potentially driving adoption among healthcare providers. The therapy's novel mechanism—targeting IL-2 receptors and depleting immunosuppressive T-cells—could meaningfully impact patient outcomes. With its influence on treatment practices and insurance coverage, this approval may significantly expand the reach of LYMPHIR in the U.S. market, especially benefiting Medicare and Medicaid patients. Anyways... Make sure to check out our full report from this morning! Until Next Time, -Damian | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Sponsored by Lifewater Media. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| You've received it because you've subscribed to our newsletter or are a member of ZipTraderU. |
| This email was sent to phanxuanhoa60.trade1357@blogger.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated nineteen thousand five hundred USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Pharmaceuticals Inc. (CTXR) on November 11, 2024. ZipTrader may receive additional campaigns in the future by Lifewater Media to distribute media for Citius Pharmaceuticals Inc. (CTXR). ZipTrader has been compensated seventeen thousand five hundred USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Pharmaceuticals Inc. (CTXR) from August 4, 2024 to August 5, 2024. ZipTrader has been compensated twenty thousand USD by ACH Bank Transfer by Lifewater Media to distribute media for Citius Pharmaceuticals Inc. (CTXR) on January 25, 2023. ZipTrader has been compensated fifteen thousand USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Oncology Inc.* (CTOR) on September 23, 2024. As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Citius Pharmaceuticals Inc. (CTXR). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Citius Pharmaceuticals Inc. (CTXR), increased trading volume, and possibly an increased share price of Citius Pharmaceuticals Inc. (CTXR), which may or may not be temporary and decrease once the marketing arrangement has ended. *Citius Oncology Inc. (CTOR) is a subsidiary of Citius Pharmaceuticals Inc. (CTXR) |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service.See Our Advertisement/Sponsored Stock Disclaimer. |
| | |
|
|
|---|
|
|
|
ليست هناك تعليقات:
إرسال تعليق